IL250583D0 - Anti-tigit antibodies - Google Patents

Anti-tigit antibodies

Info

Publication number
IL250583D0
IL250583D0 IL250583A IL25058317A IL250583D0 IL 250583 D0 IL250583 D0 IL 250583D0 IL 250583 A IL250583 A IL 250583A IL 25058317 A IL25058317 A IL 25058317A IL 250583 D0 IL250583 D0 IL 250583D0
Authority
IL
Israel
Prior art keywords
tigit antibodies
tigit
antibodies
Prior art date
Application number
IL250583A
Other languages
Hebrew (he)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US201462038912P priority Critical
Priority to US201562126733P priority
Priority to PCT/US2015/045447 priority patent/WO2016028656A1/en
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of IL250583D0 publication Critical patent/IL250583D0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IL250583A 2014-08-19 2017-02-13 Anti-tigit antibodies IL250583D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
US201462038912P true 2014-08-19 2014-08-19
US201562126733P true 2015-03-02 2015-03-02
PCT/US2015/045447 WO2016028656A1 (en) 2014-08-19 2015-08-17 Anti-tigit antibodies

Publications (1)

Publication Number Publication Date
IL250583D0 true IL250583D0 (en) 2017-04-30

Family

ID=53938463

Family Applications (1)

Application Number Title Priority Date Filing Date
IL250583A IL250583D0 (en) 2014-08-19 2017-02-13 Anti-tigit antibodies

Country Status (25)

Country Link
US (4) US20160355589A1 (en)
EP (1) EP3183267A1 (en)
JP (2) JP2017532007A (en)
KR (2) KR102050082B1 (en)
CN (1) CN107148430A (en)
AP (2) AP201709765A0 (en)
AU (2) AU2015305754B2 (en)
BR (1) BR112017003108A2 (en)
CA (1) CA2957722A1 (en)
CL (2) CL2017000310A1 (en)
CR (1) CR20170060A (en)
DO (1) DOP2017000046A (en)
EA (1) EA036311B1 (en)
GT (1) GT201700033A (en)
IL (1) IL250583D0 (en)
MD (1) MD20170032A2 (en)
MX (1) MX2017002229A (en)
NI (1) NI201700019A (en)
PE (1) PE20170289A1 (en)
PH (1) PH12017500296A1 (en)
SG (1) SG11201701161QA (en)
TN (1) TN2017000024A1 (en)
TW (1) TW201609813A (en)
UA (1) UA122395C2 (en)
WO (1) WO2016028656A1 (en)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT2758073T (en) 2011-09-23 2019-01-10 Oncomed Pharmaceuticals, Inc. Vegf/dll4 binding agents and uses thereof
CR20160319A (en) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Pd-1 antibody, binding fragment of this antigen and medical use of this
EA201692458A1 (en) 2014-05-28 2017-06-30 Агенус Инк. ANTI-GITR ANTIBODIES AND METHODS OF THEIR APPLICATION
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
MX2017014188A (en) 2015-05-07 2018-04-10 Agenus Inc Anti-ox40 antibodies and methods of use thereof.
TW201718646A (en) 2015-05-28 2017-06-01 安可美德藥物股份有限公司 TIGIT-binding agents and uses thereof
CN108290936A (en) 2015-08-14 2018-07-17 默沙东公司 Anti- TIGIT antibody
JP2018527952A (en) 2015-09-01 2018-09-27 アジェナス インコーポレイテッド Anti-PD-1 antibody and method of use thereof
EP3344658A1 (en) 2015-09-02 2018-07-11 Yissum Research Development Company of The Herbrew University of Jerusalem Ltd. Antibodies specific to human t-cell immunoglobulin and itim domain (tigit)
BR112018006531A2 (en) * 2015-10-01 2018-12-11 Potenza Therapeutics Inc isolated antigen-binding protein (abp), isolated polynucleotide, vector, host cell, method for producing an isolated antigen-binding protein (abp), pharmaceutical composition, method for treating or preventing a disease or condition in a subject in need thereof, method for modulating an immune response in an individual in need thereof and kit
SG11201804265XA (en) 2015-12-02 2018-06-28 Agenus Inc Antibodies and methods of use thereof
AU2017228474A1 (en) 2016-03-04 2018-08-30 Abmuno Therapeutics Llc Antibodies to TIGIT
MX2018014387A (en) 2016-05-27 2019-03-14 Agenus Inc Anti-tim-3 antibodies and methods of use thereof.
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
TW201803905A (en) 2016-06-20 2018-02-01 克馬伯有限公司 Multispecific antibodies for immuno-oncology
AU2017313405A1 (en) 2016-08-17 2019-02-28 Compugen Ltd. Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereof
BR112019007369A2 (en) 2016-10-11 2019-07-16 Agenus Inc anti-lag-3 antibodies and methods of use
CA3044664A1 (en) * 2016-11-30 2018-06-07 Oncomed Pharmaceuticals, Inc. Methods for treatment of cancer comprising tigit-binding agents
WO2018102746A1 (en) * 2016-12-02 2018-06-07 Rigel Pharmaceuticals, Inc. Antigen binding molecules to tigit
US10232053B2 (en) 2016-12-30 2019-03-19 Trieza Therapeutics, Inc. Immunomodulatory oncolytic adenoviral vectors, and methods of production and use thereof for treatment of cancer
US10537637B2 (en) 2017-01-05 2020-01-21 Gensun Biopharma Inc. Checkpoint regulator antagonists
WO2018187191A1 (en) 2017-04-03 2018-10-11 Jounce Therapeutics, Inc Compositions and methods for the treatment of cancer
EP3612201A1 (en) 2017-04-21 2020-02-26 Sillajen, Inc. Oncolytic vaccinia virus and checkpoint inhibitor combination therapy
WO2018200430A1 (en) 2017-04-26 2018-11-01 Bristol-Myers Squibb Company Methods of antibody production that minimize disulfide bond reduction
AU2018261080A1 (en) * 2017-05-02 2019-11-07 Merck Sharp & Dohme Corp. Stable formulations of anti-TIGIT antibodies alone and in combination with programmed death receptor 1 (PD-1) antibodies and methods of use thereof
WO2018220446A1 (en) 2017-06-01 2018-12-06 Compugen Ltd. Triple combination antibody therapies
WO2018229163A1 (en) 2017-06-14 2018-12-20 King's College London Methods of activating v delta 2 negative gamma delta t cells
GB201709808D0 (en) * 2017-06-20 2017-08-02 Kymab Ltd Antibodies
BE1025333B1 (en) * 2017-07-27 2019-01-23 Iteos Therapeutics S.A. ANTI-TIGIT ANTIBODIES
WO2019023504A1 (en) 2017-07-27 2019-01-31 Iteos Therapeutics Sa Anti-tigit antibodies
SG11202000660QA (en) 2017-07-27 2020-02-27 Iteos Therapeutics Sa Anti-tigit antibodies
WO2019062832A1 (en) * 2017-09-29 2019-04-04 江苏恒瑞医药股份有限公司 Tigit antibody, antigen-binding fragment thereof, and medical use thereof
TW201930359A (en) * 2017-12-30 2019-08-01 英屬開曼群島商百濟神州有限公司 Anti-TIGIT antibodies and their use as therapeutics and diagnostics
KR20200109313A (en) * 2018-01-15 2020-09-22 난징 레전드 바이오테크 씨오., 엘티디. Antibodies to TIGIT and variants thereof
EP3746119A1 (en) * 2018-02-01 2020-12-09 Merck Sharp&Dohme Corp. Methods for treating cancer or infection using a combination of an anti-pd-1 antibody, an anti-lag3 antibody, and an anti-tigit antibody
WO2019154415A1 (en) * 2018-02-06 2019-08-15 I-Mab Antibodies to t cell immunoreceptor with ig and itim domains (tigit) and uses thereof
WO2019168382A1 (en) * 2018-02-28 2019-09-06 Yuhan Corporation Anti-tigit antibodies and uses thereof
WO2019191133A1 (en) 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
AU2019264965A1 (en) 2018-05-09 2020-11-19 Nectin Therapeutics Ltd. Antibodies specific to human Nectin4
WO2019232484A1 (en) 2018-06-01 2019-12-05 Compugen Ltd Anti-pvrig/anti-tigit bispecific antibodies and methods of use
WO2020006509A1 (en) 2018-06-29 2020-01-02 Gensun Biopharma, Inc. Antitumor antagonists
TW202019465A (en) 2018-07-25 2020-06-01 大陸商信達生物製藥（蘇州）有限公司 Anti-tigit antibody and use thereof
US20200062859A1 (en) 2018-08-23 2020-02-27 Seattle Genetics, Inc. Anti-TIGIT Antibodies
US20200190174A1 (en) 2018-08-30 2020-06-18 HCW Biologics, Inc. Single-chain chimeric polypeptides and uses thereof
WO2020047462A2 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Methods of treating aging-related disorders
US20200071374A1 (en) 2018-08-30 2020-03-05 HCW Biologics, Inc. Multi-chain chimeric polypeptides and uses thereof
WO2020096915A1 (en) * 2018-11-05 2020-05-14 Merck Sharp & Dohme Corp. Dosing regimen of anti-tigit antibody for treatment of cancer
WO2020127377A1 (en) 2018-12-21 2020-06-25 Ose Immunotherapeutics Bifunctional anti-pd-1/il-7 molecule
WO2020144178A1 (en) 2019-01-07 2020-07-16 Iteos Therapeutics Sa Anti-tigit antibodies
WO2020165374A1 (en) 2019-02-14 2020-08-20 Ose Immunotherapeutics Bifunctional molecule comprising il-15ra
WO2020172658A1 (en) 2019-02-24 2020-08-27 Bristol-Myers Squibb Company Methods of isolating a protein
WO2020185739A1 (en) 2019-03-11 2020-09-17 Jounce Therapeutics, Inc. Anti-icos antibodies for the treatment of cancer
WO2020237221A1 (en) 2019-05-23 2020-11-26 Bristol-Myers Squibb Company Methods of monitoring cell culture media
WO2020242919A1 (en) 2019-05-29 2020-12-03 Eli Lilly And Company Tigit and pd-1/tigit-binding molecules
US10851157B2 (en) 2019-07-01 2020-12-01 Gensun Biopharma, Inc. Antagonists targeting the TGF-β pathway
CN111718415A (en) * 2020-07-03 2020-09-29 上海洛启生物医药技术有限公司 anti-TIGIT nano antibody and application thereof

Family Cites Families (97)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
DE3668186D1 (en) 1985-04-01 1990-02-15 Celltech Ltd Transformed myeloma cell line and method using the same for expressing a gene encoding an eukaryontic polypeptide.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
AT135370T (en) 1988-12-22 1996-03-15 Kirin Amgen Inc Chemically modified granulocyte colony exciting factor
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag Bispecific and oligo-specific, mono- and oligovalent anti-body constructs, their production and use
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
ES2165851T3 (en) 1991-11-25 2002-04-01 Enzon Inc Multivalent proteins that join antigens.
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
US5714350A (en) 1992-03-09 1998-02-03 Protein Design Labs, Inc. Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US6129914A (en) 1992-03-27 2000-10-10 Protein Design Labs, Inc. Bispecific antibody effective to treat B-cell lymphoma and cell line
EP0640094A1 (en) 1992-04-24 1995-03-01 Board Of Regents The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
ES2322324T3 (en) 1992-08-21 2009-06-19 Vrije Universiteit Brussel Immumoglobulins desprovistas of light chains.
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
DK0698097T3 (en) 1993-04-29 2001-10-08 Unilever Nv Production of antibodies or (functionalized) fragments thereof derived from Camelidae heavy chain immunoglobulins
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US5532210A (en) 1994-06-08 1996-07-02 E. I. Du Pont De Nemours And Company High temperature superconductor dielectric slow wave structures for accelerators and traveling wave tubes
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
WO1998052976A1 (en) 1997-05-21 1998-11-26 Biovation Limited Method for the production of non-immunogenic proteins
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9818110D0 (en) 1998-08-19 1998-10-14 Weston Medical Ltd Needleless injectors and other devices
US6096002A (en) 1998-11-18 2000-08-01 Bioject, Inc. NGAS powered self-resetting needle-less hypodermic jet injection apparatus and method
AU764211C (en) 1998-12-01 2006-03-30 Abbvie Biotherapeutics Inc. Humanized antibodies to gamma-interferon
CA2359067C (en) 1999-01-15 2017-03-14 Genentech, Inc. Polypeptide variants with altered effector function
US7368527B2 (en) 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
JP2002539814A (en) 1999-03-26 2002-11-26 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 50 human secreted proteins
CA2369292C (en) 1999-04-09 2010-09-21 Kyowa Hakko Kogyo Co. Ltd. Method of modulating the activity of functional immune molecules
EP1229125A4 (en) 1999-10-19 2005-06-01 Kyowa Hakko Kogyo Kk Process for producing polypeptide
PT1522590E (en) 2000-06-28 2009-10-26 Glycofi Inc Methods for producing modified glycoproteins
US7449308B2 (en) 2000-06-28 2008-11-11 Glycofi, Inc. Combinatorial DNA library for producing modified N-glycans in lower eukaryotes
US6374470B1 (en) 2000-10-06 2002-04-23 Milliken & Company Face plate for spun-like textured yarn
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US7408041B2 (en) 2000-12-08 2008-08-05 Alexion Pharmaceuticals, Inc. Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof
NZ531219A (en) 2001-08-03 2007-07-27 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
EP2388265A1 (en) 2002-02-22 2011-11-23 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
US7193069B2 (en) 2002-03-22 2007-03-20 Research Association For Biotechnology Full-length cDNA
US20070134247A9 (en) 2002-04-12 2007-06-14 Ramot At Tel Aviv University Ltd. Prevention of brain inflammation as a result of induced autoimmune response
EP1575497A4 (en) 2002-09-11 2010-11-03 Genentech Inc Novel composition and methods for the treatment of psoriasis
DE60335552D1 (en) 2002-09-11 2011-02-10 Genentech Inc New composition and method for the treatment of immune diseases
HUE034378T2 (en) 2002-10-16 2018-02-28 Purdue Pharma Lp Antibodies that bind cell-associated CA 125/O722P and methods of use thereof
US20090047213A1 (en) * 2003-04-14 2009-02-19 Young David S F Cytotoxicity mediation of cells evidencing surface expression of CD59
US7410483B2 (en) 2003-05-23 2008-08-12 Novare Surgical Systems, Inc. Hand-actuated device for remote manipulation of a grasping tool
US7312320B2 (en) 2003-12-10 2007-12-25 Novimmune Sa Neutralizing antibodies and methods of use thereof
WO2005120571A2 (en) 2004-06-07 2005-12-22 Ramot At Tel Aviv University Ltd. Method of passive immunization against disease or disorder characterized by amyloid aggregation with diminished risk of neuroinflammation
WO2006014679A1 (en) 2004-07-21 2006-02-09 Glycofi, Inc. Immunoglobulins comprising predominantly a glcnac2man3glcnac2 glycoform
ES2772674T3 (en) 2005-05-12 2020-07-08 Zymogenetics Inc Compositions and methods for modulating immune responses
PL1904104T3 (en) 2005-07-08 2014-02-28 Biogen Ma Inc Sp35 antibodies and uses thereof
AU2008234020B2 (en) 2007-04-03 2013-02-07 Amgen Research (Munich) Gmbh Cross-species-specific CD3-epsilon binding domain
EP3605088A1 (en) * 2008-04-09 2020-02-05 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
AU2015202123B2 (en) 2008-04-09 2017-06-15 Genentech, Inc. Novel compositions and methods for the treatment of immune related diseases
US8858949B2 (en) 2009-08-06 2014-10-14 Immunas Pharma, Inc. Antibodies that specifically bind to a beta oligomers and use thereof
WO2011044311A2 (en) 2009-10-09 2011-04-14 Merck Sharp & Dohme Corp. Generation, characterization and uses thereof of anti-her 3 antibodies
BR112012013581A8 (en) 2009-12-05 2017-12-26 Univ Heidelberg Ruprecht Karls apicomplex ferline-based malaria vaccines, ferline-like proteins and other proteins containing the c2 domain
EP2580238A1 (en) 2010-06-09 2013-04-17 Zymogenetics, Inc. Dimeric vstm3 fusion proteins and related compositions and methods
BR112013004266A8 (en) 2010-08-23 2018-01-02 Univ Texas anti-ox40 antibodies and methods of use.
UA112434C2 (en) 2011-05-27 2016-09-12 Ґлаксо Ґруп Лімітед Antigen-binding protein that specifically binds to vsma
US9205144B2 (en) 2011-06-03 2015-12-08 Dana-Farber Cancer Institute, Inc. Identification of conserved peptide blocks in homologous polypeptides
KR20130062168A (en) 2011-12-02 2013-06-12 고려대학교 산학협력단 Recombinant fluorescent nanoparticles
WO2013130905A1 (en) 2012-02-29 2013-09-06 Gilead Biologics, Inc. Antibodies to matrix metalloproteinase 9
WO2013148316A1 (en) 2012-03-29 2013-10-03 Biogen Idec Ma Inc. Biomarkers for use in integrin therapy applications
WO2013151999A1 (en) 2012-04-02 2013-10-10 President And Fellows Of Harvard College Cancer treatment and immune system regulation through fat10 pathway inhibition
AU2013271515A1 (en) 2012-06-06 2015-01-15 Oncomed Pharmaceuticals, Inc. Binding agents that modulate the Hippo pathway and uses thereof
HUE043903T2 (en) 2012-12-03 2019-09-30 Squibb Bristol Myers Co Enhancing anti-cancer activity of immunomodulatory fc fusion proteins
EP2928483A4 (en) * 2012-12-04 2016-06-08 Oncomed Pharm Inc Immunotherapy with binding agents
CN103073644B (en) * 2012-12-31 2014-03-12 中国科学技术大学 Specific anti-mouse TIGIT monoclonal antibody and preparation method, identification and application thereof
US20140314741A1 (en) 2013-04-18 2014-10-23 Developmen Center For Biotechnology Human Antibody against Interleukin-20 and Treatment for Inflammatory Diseases
WO2015009856A2 (en) 2013-07-16 2015-01-22 Genentech, Inc. Methods of treating cancer using pd-1 axis binding antagonists and tigit inhibitors
WO2015127273A1 (en) 2014-02-21 2015-08-27 Medimmune, Llc Anti-pcsk9~glp-1 fusions and methods for use
PE20170140A1 (en) 2014-07-16 2017-03-30 Genentech Inc Methods to treat cancer with inhibitors tigit and anticancer agents
WO2016028656A1 (en) 2014-08-19 2016-02-25 Merck Sharp & Dohme Corp. Anti-tigit antibodies
KR20170072343A (en) 2014-11-06 2017-06-26 제넨테크, 인크. Combination therapy comprising ox40 binding agonists and tigit inhibitors
DK3221346T3 (en) 2014-11-21 2020-10-12 Squibb Bristol Myers Co ANTIBODIES INCLUDING MODIFIED CONSTANT AREAS OF THE HEAVY CHAIN
MA40662A1 (en) 2014-12-23 2020-06-30 Squibb Bristol Myers Co Antibodies against tigit
TW201718646A (en) 2015-05-28 2017-06-01 安可美德藥物股份有限公司 TIGIT-binding agents and uses thereof
PE20181046A1 (en) 2015-09-25 2018-07-03 Genentech Inc Tigit antibodies and methods of use

Also Published As

Publication number Publication date
US10618958B2 (en) 2020-04-14
US20160355589A1 (en) 2016-12-08
EA201790413A1 (en) 2017-08-31
GT201700033A (en) 2019-09-30
KR20170041272A (en) 2017-04-14
US20170198042A1 (en) 2017-07-13
DOP2017000046A (en) 2017-08-31
AU2015305754A1 (en) 2017-02-23
CL2019001926A1 (en) 2019-11-29
MX2017002229A (en) 2017-05-09
NI201700019A (en) 2017-03-08
MD20170032A2 (en) 2017-08-31
EA036311B1 (en) 2020-10-26
KR102050082B1 (en) 2019-11-29
CA2957722A1 (en) 2016-02-25
JP2020162614A (en) 2020-10-08
KR20190133078A (en) 2019-11-29
EP3183267A1 (en) 2017-06-28
TN2017000024A1 (en) 2018-07-04
SG11201701161QA (en) 2017-03-30
UA122395C2 (en) 2020-11-10
US20180066055A1 (en) 2018-03-08
AP2017009765A0 (en) 2017-02-28
TW201609813A (en) 2016-03-16
US20200270346A1 (en) 2020-08-27
JP2017532007A (en) 2017-11-02
BR112017003108A2 (en) 2017-12-05
AU2015305754B2 (en) 2018-10-25
CN107148430A (en) 2017-09-08
CR20170060A (en) 2017-04-18
PE20170289A1 (en) 2017-04-05
CL2017000310A1 (en) 2017-08-18
WO2016028656A1 (en) 2016-02-25
AU2019200426A1 (en) 2019-02-07
PH12017500296A1 (en) 2017-06-28
AP201709765A0 (en) 2017-02-28

Similar Documents

Publication Publication Date Title
HRP20191704T1 (en) Multispecific antibodies
ZA201704981B (en) Antibodies to tigit
IL250415D0 (en) Anti-pd-l1 antibodies
HK1217861A1 (en) Wifi-coordinated laa-lte
ZA201700551B (en) Anti-pd-1 antibodies
PL3227332T3 (en) Multispecific antibodies
IL250583D0 (en) Anti-tigit antibodies
EP3212231A4 (en) Anti-tim-3 antibodies
LT3221346T (en) Antibodies comprising modified heavy constant regions
IL252004D0 (en) Domain-exchanged antibody
EP3212229A4 (en) Anti-tim-3 antibodies
SG10201601719RA (en) Anti-LAG-3 Antibodies
GB201410907D0 (en) No details
IL251963D0 (en) Anti-pd-1 antibodies
GB201411320D0 (en) Antibody construct
GB201601073D0 (en) Antibodies
HK1253507A1 (en) Anti-ror1 antibodies
GB201414823D0 (en) Multispecific antibodies
GB2528557B (en) Soundbar
HUE044950T2 (en) Schienenmesssystem
IL257798D0 (en) Anti-lag-3 antibodies
ZA201900373B (en) Anti-tim-3 antibodies
AU361515S (en) Dishrack
IL259048D0 (en) Anti-ror1 antibodies
GB201411420D0 (en) Antibody constructs